Bill C-17 explained in plain English
An Act to amend the Food and Drugs Act
Federal Parliament bill summary, status, timeline, sponsor, votes, and official sources.
At a glance
Official Parliament of Canada snapshot for 41st Parliament, 2nd Session. MP vote breakdowns appear when the House of Commons publishes a recorded division export for that bill. Senate and House stage details include official debate/sitting links when LEGISinfo publishes them.
Our plain-language take, written for civic education.
Source: By PoliticalData.ca
Bill C-17 strengthens federal safety oversight of drugs and medical devices by expanding the Minister's powers to gather safety information, issue recalls and orders, and disclose confidential information when there is a serious health risk, while increasing reporting obligations for health care institutions and imposing stronger penalties for non-compliance.
Bill C-17, also known as the Protecting Canadians from Unsafe Drugs Act (Vanessa's Law), amends the federal Food and Drugs Act to strengthen the safety oversight of therapeutic products (drugs and medical devices) throughout their life cycle. The bill gives the federal Minister of Health new powers to order persons to provide safety information about therapeutic products, to disclose confidential business information when there is a serious health risk, to order recalls or corrective actions, and to require assessments and monitoring. The bill also creates new obligations for health care institutions to report serious adverse drug reactions and medical device incidents to the Minister. It establishes stronger penalties for contraventions, including larger fines and longer prison sentences for offences related to therapeutic products. The bill introduces new definitions for therapeutic products, therapeutic product authorizations, and confidential business information, and requires greater public transparency in regulatory decisions affecting these products.
- Expands the definition of 'device' (medical device) to clarify what products fall under the Food and Drugs Act oversight
- Adds new definitions for 'therapeutic product' (drugs and devices but not natural health products), 'therapeutic product authorization' (licences and approvals), and 'confidential business information'
- Grants the Minister power to order persons to provide information about therapeutic products if the Minister believes they may present a serious risk of injury to human health
- Allows the Minister to disclose confidential business information without consent when there is a serious health risk or when disclosure relates to protecting human health or public safety
- Authorizes the Minister to order changes to labels or packaging of therapeutic products when necessary to prevent injury to health
- Authorizes the Minister to order recalls of therapeutic products that present a serious or imminent risk, with option for corrective action instead of return in some cases
- Allows the Minister to authorize sale of recalled products under specified conditions
- Requires health care institutions designated by regulation to report serious adverse drug reactions and medical device incidents to the Minister
- Requires holders of therapeutic product authorizations to provide safety information to the Minister, including information about risks, labelling changes, and recalls outside Canada
- Requires clinical trial authorizations to make prescribed information public within prescribed timeframes
- Authorizes the Minister to order assessments of therapeutic products and to order compilation of safety information and monitoring
- Makes all Minister's orders related to therapeutic products publicly available
- Prohibits false or misleading statements to the Minister regarding therapeutic products
- Creates new offence categories with enhanced penalties: up to $5,000,000 fine and 2 years imprisonment on indictment for standard contraventions; up to $1,000,000 fine and 2 years imprisonment for repeat summary convictions for more serious offences involving knowingly causing serious risk
- Establishes that due diligence is a defence for most offences, but not for offences involving knowingly causing serious health risk or making false statements
- Requires courts to consider harm, risk of harm, and vulnerability of consumers when sentencing for therapeutic product offences
- Makes directors, officers, and agents of corporations liable for offences committed by their organization
- Expands regulation-making power to govern issuance, suspension, and revocation of therapeutic product authorizations, impose conditions, and require public disclosure of regulatory decisions with reasons
- Clarifies that regulations can incorporate documents by reference regardless of source
- Requires the Minister to consider existing information management systems before recommending regulations that would impose administrative burdens
- Strengthens the Minister's evidence in prosecutions through analyst certificates
- Manufacturers, importers, and sellers of drugs and medical devices (therapeutic products)
- Holders of therapeutic product authorizations (licences and approvals)
- Health care institutions (hospitals, clinics, and other prescribed facilities) that must report adverse reactions and device incidents
- Companies that conduct clinical trials with therapeutic products
- Persons or organizations with confidential business information related to therapeutic products
- The general public and consumers who use therapeutic products
- The federal Minister of Health and Health Canada officials who enforce the Act
- Directors, officers, and agents of organizations that violate the Act
- Persons must comply with any order from the Minister to provide information about therapeutic products that may present a serious health risk
- Persons holding therapeutic product authorizations must comply with any conditions imposed or amended by the Minister under regulations
- Holders of authorizations for clinical trials must ensure prescribed information is made public within prescribed timeframes and manner
- Health care institutions must provide the Minister with prescribed information about serious adverse drug reactions and medical device incidents within prescribed timeframes
- Persons who sell therapeutic products must comply with recall orders issued by the Minister, or else face criminal penalties, unless authorized otherwise
- Persons cannot knowingly make false or misleading statements to the Minister regarding therapeutic products
- Sellers of therapeutic products must comply with orders to modify labels or packaging when ordered by the Minister
- Holders of therapeutic product authorizations must provide the Minister with safety information they receive or become aware of regarding risks, labelling changes, and regulatory actions outside Canada
- The Minister has the right to disclose confidential business information when necessary to protect health or safety or when dealing with a serious health risk
- The public has the right to access all orders made by the Minister under sections 21.1 to 21.32
- The public has the right to access regulatory decisions about issuance, amendment, suspension, and revocation of therapeutic product authorizations, along with the reasons for those decisions
- Royal assent received: 6 November 2014
- Some sections (4, 6(2), 10, 11) come into force on a day to be fixed by order of the Governor in Council
- Other sections (5, 6(3), 6(4)) come into force on a different day to be fixed by order of the Governor in Council
- The definition of 'therapeutic product authorization' applies to authorizations issued before the section comes into force
- Potential significant financial penalties for companies and individuals violating the Act, ranging from $250,000 to $5,000,000 depending on the offence and whether it is a first or subsequent offence
- Administrative costs for health care institutions to establish systems for reporting serious adverse drug reactions and medical device incidents
- Administrative costs for therapeutic product manufacturers and importers to respond to Minister's orders for information, assessments, and safety monitoring
- Potential costs for companies to implement corrective actions on recalled products rather than collecting returns
- Contravention of the Act or regulations relating to therapeutic products: up to $5,000,000 fine and/or 2 years imprisonment on indictment; on summary conviction, first offence up to $250,000 fine and/or 6 months imprisonment; subsequent offence up to $500,000 fine and/or 18 months imprisonment
- Making false or misleading statements to the Minister regarding therapeutic products, or knowingly causing serious risk of injury to health: indictment with discretionary fine and/or up to 5 years imprisonment; on summary conviction, first offence up to $500,000 fine and/or 18 months imprisonment; subsequent offence up to $1,000,000 fine and/or 2 years imprisonment
- Each day an offence continues constitutes a separate offence
- Directors, officers, agents, and mandataries of organizations are personally liable for offences committed by their organization if they directed, authorized, assented to, or acquiesced in the offence
- Due diligence is a defence to most charges, except for charges of making false statements or knowingly causing serious health risk
- Courts must consider the harm or risk of harm and the vulnerability of consumers when sentencing for therapeutic product offences
- The bill text does not specify which health care institutions are 'prescribed' to report adverse reactions and incidents—this will be determined by future regulations
- The bill does not provide specific timelines for when health care institutions must report incidents, stating only that reporting must occur 'within the prescribed time'
- The definition of 'serious adverse drug reaction' and 'medical device incident' are to be defined by regulation, not in the Act itself
- The bill does not specify which therapeutic products or types of authorizations will be subject to requirements for public disclosure of clinical trial information
- The criteria for when information 'ceases to be' confidential business information are to be determined by regulation
- The bill does not explain how the Minister will determine that a product 'may present' a serious risk or 'presents a serious or imminent risk'—these are subjective assessments
- The bill does not specify what 'corrective action' means in the context of recalls, leaving this to be defined through regulations or case-by-case application
- The commencement date for most provisions is to be fixed by order of the Governor in Council, meaning the bill's key provisions do not automatically come into force on royal assent
- The bill references 'prescribed' timeframes and manners for various requirements, but these are not provided in the bill itself
- It is unclear whether the ban on selling recalled products applies retroactively to recalls ordered before the Act comes into force
The Act is amended to add new sections creating powers for the Minister to order information provision, disclose confidential information, order recalls and label changes, and require assessments and monitoring of therapeutic products. New offence categories and penalties are introduced. Existing regulation-making powers are expanded to cover therapeutic product authorizations, public disclosure of decisions, and health care institution reporting requirements.
Source: Multiple sections amended: Section 2 (definitions), new sections 21.1-21.8, 21.31-21.32, section 30 (regulation-making), section 31 and following (offences and penalties)
Generated using AI from official bill text. Not legal advice. It is written by PoliticalData.ca for civic education, automatically checked and spot-reviewed before publishing.
Official textThe official summary published alongside the bill, shown exactly as written.
Source: Parliament of Canada (LEGISinfo)
A legislative summary is currently being prepared for this bill by the Parliamentary Information and Research Service of the Library of Parliament. Meanwhile, the following executive summary is available. On 6 December 2013, the Minister of Health introduced Bill C-17, An Act to amend the Food and Drugs Act (Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)) in the House of Commons and it was given first reading. Bill C-17 amends the Food and Drugs Act regarding therapeutic products in order to improve safety by introducing measures to, among other things, • strengthen safety oversight of therapeutic products throughout their life cycle; and • improve reporting by certain health care institutions of serious adverse drug reactions and medical device incidents that involve therapeutic products.
This is the official summary published by the Parliament of Canada, shown verbatim. Not legal advice. PoliticalData.ca did not write or edit this text.
View on LEGISinfoParliamentary Process
The Senate held its first reading of Bill C-17 on June 17, 2014, which subsequently passed through both chambers and received royal assent.
This artifact details the first reading of Bill C-17 in the Senate on June 17, 2014. This procedural step marks the formal introduction of the bill into the Senate. The bill was later passed and received royal assent on November 6, 2014, becoming chapter 24 of the Statutes of Canada, 2014. The artifact also outlines the subsequent stages the bill went through in both the Senate and the House of Commons, including readings, committee reviews, and report stages, leading up to its final assent.
During a Senate sitting on June 16, 2014, tributes were paid to retiring Senator Dallaire, proposed regulations were tabled, and debates occurred on various bills, including extensive discussion on privacy and data protection in relation to Bill S-4, culminating in Senator Dallaire's final address.
On June 16, 2014, the Senate began proceedings with tributes to Senator Roméo Dallaire upon his retirement and congratulations to Senator Wilfred P. Moore on receiving an honorary degree. The Senate also received several committee reports and tabled proposed regulations. Bills were introduced, read for the first time, and debated at various stages. A significant portion of the sitting involved a detailed debate on Bill S-4, concerning amendments to the Personal Information Protection and Electronic Documents Act, with extensive discussion on the implications of a recent Supreme Court of Canada decision regarding privacy and data disclosure. Senator Dallaire delivered his final speech, reflecting on his time in the Senate and his future humanitarian work, before the Senate adjourned.
The Senate completed its Second Reading stage for Bill C-17 on September 18, 2014, leading to subsequent committee review and eventual Royal Assent.
This artifact details the Senate's Second Reading stage for Bill C-17, an Act to amend the Food and Drugs Act. This stage involved speeches and was completed on September 18, 2014, after which the bill was referred to a committee. The process led to the bill receiving Royal Assent on November 6, 2014, and becoming chapter 24 of the Statutes of Canada 2014.
During a Senate sitting on September 16, 2014, the second reading debate of Bill C-17, "Vanessa's Law," concerning drug safety, was initiated and subsequently adjourned.
On September 16, 2014, the Senate of Canada convened for a sitting that included various procedural matters, tributes, and debates. Key among these was the second reading debate of Bill C-17, An Act to amend the Food and Drugs Act, also known as "Vanessa's Law." Senator Judith Seidman moved second reading, explaining that the bill aimed to improve prescription drug safety by giving Health Canada enhanced powers for oversight and enforcement. The debate on Bill C-17 was adjourned, meaning it was not completed during this sitting and would continue at a later date. Other proceedings included tabling reports, inquiries, and debates on other bills and motions. The sitting concluded with the Senate adjourning until September 18, 2014.
During a Senate debate on September 16, 2014, Senator Judith Seidman introduced Bill C-17 (Vanessa's Law) to enhance prescription drug safety, sparking discussion on its provisions and Health Canada's capacity to implement them, before the debate was adjourned.
This document is a record of a Senate debate on September 16, 2014. The main focus of the debate was Bill C-17, also known as "Vanessa's Law," which aims to improve the safety of prescription drugs in Canada. Senator Judith Seidman sponsored the bill and explained its key provisions, including mandatory reporting of adverse drug reactions by healthcare institutions, requirements for drug companies to revise labels with risk information, and the Minister's power to recall unsafe products. The debate also touched upon the potential penalties for violations, including fines and jail time. Several senators raised concerns about Health Canada's capacity to implement these changes, particularly in light of previous budget cuts. The debate on Bill C-17 was adjourned, meaning it was not fully concluded on this day.
In a Senate sitting on September 18, 2014, Bill C-17, concerning amendments to the Food and Drugs Act, was debated at second reading and referred to committee, with senators discussing its merits and potential improvements.
On September 18, 2014, the Senate of Canada held a sitting that included various discussions and procedural matters. A significant portion of the sitting was dedicated to the second reading debate of Bill C-17, An Act to amend the Food and Drugs Act, also known as "Vanessa's Law." During this debate, Senator Art Eggleton spoke in favour of the bill, highlighting its importance in improving drug safety regulations, while also suggesting areas for improvement. Following the debate, Bill C-17 was referred to the Standing Senate Committee on Social Affairs, Science and Technology. The sitting also featured discussions on other matters, including the ratification of the Convention on Cluster Munitions, the establishment of Pope John Paul II Day, breast density awareness, amendments to the Income Tax Act, and a report on conflict of interest for senators. Additionally, there were tributes to military regiments, discussions on youth empowerment, and remarks regarding the Access to Information Act and Privacy Act annual report.
During the Senate's second reading debate on Bill C-17, "An Act to amend the Food and Drugs Act," senators discussed proposed changes to drug safety regulations, with one senator supporting the bill while suggesting improvements.
This document is a record of the Senate's second reading debate on Bill C-17, "An Act to amend the Food and Drugs Act." Senator Art Eggleton spoke in favour of the bill, highlighting its importance in updating drug regulation laws that had not been significantly changed in over 50 years. He noted that the bill, also known as "Vanessa's Law," incorporates recommendations from Senate committee reports on pharmaceutical safety. Senator Eggleton detailed how the bill would empower the Health Minister to recall unsafe drugs, compel manufacturers to update drug labels with clear risk information, and require manufacturers to provide crucial drug safety and test data. He also mentioned stronger penalties for non-compliance. However, he raised concerns that the bill could be improved, particularly regarding potential manufacturer lawsuits against the government for recalling drugs, the definition of "prescribed health care institutions" for reporting adverse reactions, and the transparency of clinical trial data. He also questioned Health Canada's capacity to enforce new measures due to existing funding and staffing limitations. The debate also included discussions on other unrelated matters such as military anniversaries, environmental initiatives, youth empowerment, international relations, and various other bills and reports before the Senate.
The Senate Committee concluded its consideration of Bill C-17 on October 9, 2014, after multiple meetings.
The Senate Committee completed its review of Bill C-17 on October 9, 2014. The records provided list the dates when the committee met to consider the bill, but do not contain the details of the discussions or any amendments proposed or adopted. This stage is part of the legislative process before the bill is considered for final approval in the Senate.
During a Senate sitting on October 9, 2014, the Social Affairs, Science and Technology Committee presented its report on Bill C-17 without amendments, and other routine parliamentary business and debates occurred.
On October 9, 2014, the Senate held a sitting where various matters were discussed. A key procedural event was the presentation of the Fourteenth Report of the Social Affairs, Science and Technology Committee regarding Bill C-17, An Act to amend the Food and Drugs Act. The committee reported the bill without amendment. The sitting also included discussions on Canadian Library Month, Mental Illness Awareness Week, the Duke of Edinburgh's Award, tributes to the late Ulrick Chérubin, the National CCSVI Society Conference, the "Rolling Rampage on the Hill" event, and visitors in the gallery. Other legislative items included debates and referrals to committees concerning the Criminal Code, the Corrections and Conditional Release Act, and firearms control. There was also a discussion about the Commissioner of Official Languages' report on program reductions and a study on bee health.
The Senate completed the third reading of Bill C-17, An Act to amend the Food and Drugs Act, on October 23, 2014, after which it received Royal Assent.
This record details the Senate's third reading stage for Bill C-17, An Act to amend the Food and Drugs Act. This procedural step was completed on October 23, 2014. The bill subsequently received Royal Assent on November 6, 2014, becoming chapter 24 of the Statutes of Canada, 2014. The artifact lists various procedural steps in both the Senate and House of Commons, including first and second readings, committee considerations, report stages, and third readings, along with dates and some speaker attributions for key speeches. It also indicates that the bill was agreed to at third reading in the Senate on October 21 and October 23, 2014.
On October 21, 2014, the Senate observed a moment of silence for a soldier, debated and passed Bill S-6, began debate on Bill C-36, and adopted a motion to grant honorary Canadian citizenship to Malala Yousafzai, while the third reading debate on Bill C-17 was adjourned.
This record details a sitting of the Senate on October 21, 2014. The Senate observed a moment of silence for a fallen soldier. Several senators spoke on various topics, including military missions, historical events, cultural practices, health initiatives, autism awareness, and committee reports. The Senate also proceeded with third reading debates on Bill C-17 (An Act to amend the Food and Drugs Act) and Bill S-6 (An Act to amend the Yukon Environmental and Socio-economic Assessment Act and the Nunavut Waters and Nunavut Surface Rights Tribunal Act). Bill C-17's third reading debate was adjourned, while Bill S-6 was read a third time and passed. The Senate also began second reading debate on Bill C-36 (Protection of Communities and Exploited Persons Act), which was then referred to committee. A message from the House of Commons to grant honorary Canadian citizenship to Malala Yousafzai was adopted. Several other committee reports were tabled, and various notices of motions and adjourned debates were noted.
On October 23, 2014, the Senate began its sitting with tributes to victims of the previous day's attack on Parliament Hill, after which it proceeded to debate and pass Bill C-17, An Act to amend the Food and Drugs Act, at its third reading.
On October 23, 2014, the Senate was in session. The day began with prayers and a moment of silence to honour Corporal Nathan Cirillo, who was killed the previous day during an attack on Parliament Hill. Senators from both the government and opposition benches spoke, expressing condolences to the families of Corporal Cirillo and Warrant Officer Patrice Vincent, and commending the courage of security forces. They emphasized the resilience of Parliament and Canada's commitment to its values of freedom and democracy. Following these tributes, the Senate proceeded with its agenda. The debate on Bill C-17, An Act to amend the Food and Drugs Act, reached its third reading. Senator Art Eggleton spoke, indicating his support for the bill despite having proposed amendments in committee that were not adopted. These proposed amendments concerned changing the word "may" to "shall" in certain sections to ensure action, providing legal protection for the minister against lawsuits from the pharmaceutical industry, and expediting committee review of major regulations. He also raised concerns about Health Canada's funding and its ability to effectively implement the bill given past resource constraints and inspection issues. Despite these concerns, he reiterated his support for the bill, calling it a step in the right direction. The Senate then adopted the motion for third reading and passed Bill C-17. Following this, the Senate adjourned until October 28, 2014. Other matters addressed included tabling reports from parliamentary delegations and initiating debate on various inquiries and committee studies.
Bill C-17, concerning amendments to the Food and Drugs Act, completed its first reading in the House of Commons on December 6, 2013, and later received Royal Assent on November 6, 2014.
This record shows that Bill C-17, An Act to amend the Food and Drugs Act, completed its first reading in the House of Commons on December 6, 2013. This is the initial stage where a bill is formally introduced to the House. The bill later received Royal Assent on November 6, 2014, becoming a statute. The artifact includes a timeline of subsequent stages the bill went through in both the House of Commons and the Senate, including readings, committee considerations, and report stages, but does not detail the content of the discussions or amendments made during those stages.
The House of Commons commenced the first reading of Bill C-17, An Act to amend the Food and Drugs Act, during a sitting that included other parliamentary business.
On December 6, 2013, the House of Commons proceeded with the first reading of Bill C-17, An Act to amend the Food and Drugs Act. The artifact provided is a record of a House of Commons sitting where various items were discussed, including government orders, statements by members, and oral questions. The introduction of Bill C-17 was a procedural step in its legislative journey.
The House of Commons completed the second reading of Bill C-17 on May 30, 2014, after which it was referred to committee.
This record details the completion of the second reading stage for Bill C-17 in the House of Commons on May 30, 2014. Following debates and major speeches on May 27, 2014, the House agreed to the second reading of the bill and referred it to a committee for further consideration. The bill later received royal assent on November 6, 2014.
In a House of Commons debate on March 28, 2014, Members discussed Bill C-17, an act to amend the Food and Drugs Act, focusing on enhancing drug safety through improved labelling and reporting of adverse reactions, and concluding with the bill being referred to committee.
During a House of Commons sitting on March 28, 2014, Members debated Bill C-17, An Act to amend the Food and Drugs Act. The Minister of Health moved that the bill be read the second time and referred to a committee. Several Members from different parties spoke, primarily focusing on the bill's purpose to enhance drug safety in Canada, inspired by personal tragedies and advocating for stronger regulations on pharmaceutical companies. Discussions included the need for better drug labelling, mandatory reporting of adverse drug reactions, and increased powers for the Minister of Health to recall unsafe drugs. Some Members also discussed the broader implications of pharmaceutical industry practices and the need for ongoing improvements in drug safety legislation. The debate concluded with the bill being referred to a committee.
During the House of Commons second reading debate on Bill C-17, members from multiple parties expressed support for the bill aimed at improving drug safety, with the bill's sponsor sharing a personal story that motivated his advocacy.
During the second reading debate on Bill C-17, the sponsor of the bill, Mr. Terence Young, delivered a powerful speech detailing the personal tragedy that motivated him to address drug safety. He highlighted concerns about the influence of "big pharma" on medical practices, the lack of adequate drug safety warnings, and the high number of deaths and injuries caused by prescription drugs when used as directed. Other members of Parliament from various parties, including Ms. Megan Leslie (NDP) and Mr. Kevin Lamoureux (Liberal), spoke in support of the bill, acknowledging the importance of the issue and Mr. Young's advocacy. They also raised points about potential amendments and the need for further action on drug safety and transparency in clinical trials. The discussion touched upon the bill's potential to empower the Minister of Health to recall unsafe drugs and compel companies to update drug labels with clearer risk information.
In a House of Commons debate, Members of Parliament discussed Bill C-17, an Act to amend the Food and Drugs Act, focusing on improving drug safety and transparency, with broad support expressed for the bill's intent and potential improvements.
During the second reading debate of Bill C-17, an Act to amend the Food and Drugs Act, Members of Parliament from various parties discussed the bill. The debate highlighted personal stories and concerns about drug safety, the influence of pharmaceutical companies, and the need for stronger regulations. Several members expressed support for the bill, while also suggesting potential amendments and further legislative actions to enhance drug safety and transparency.
In the House of Commons on May 27, 2014, members debated Bill C-17 (Vanessa's Law) at second reading, discussing its proposals to give the Minister of Health powers to recall drugs and enhance drug safety, with many supporting the bill while suggesting improvements.
On May 27, 2014, during the second reading stage in the House of Commons, members debated Bill C-17, An Act to amend the Food and Drugs Act, also known as Vanessa's Law. The debate focused on granting the Minister of Health the power to recall unsafe drugs, compel manufacturers to provide information, and impose stricter penalties on companies that fail to comply with safety regulations. While many members across different parties supported the bill in principle and agreed it was a step in the right direction, several also proposed amendments to strengthen its provisions regarding transparency, the definition of harm, and the oversight of the entire drug distribution chain. The debate also touched upon the historical context of drug safety legislation in Canada, referencing the thalidomide tragedy and the need for more robust regulatory powers.
During the second reading debate on Bill C-17, MPs discussed giving the Health Minister more power to recall unsafe drugs and improve drug safety oversight, while also suggesting amendments for greater transparency and stronger measures.
During the second reading debate of Bill C-17, an Act to amend the Food and Drugs Act, Members of Parliament discussed the proposed changes. The debate focused on strengthening the Minister of Health's powers to recall unsafe drugs, compel manufacturers to provide information, and enforce reporting of adverse drug reactions. Several members expressed support for the bill as a step in the right direction but also raised concerns that it did not go far enough, suggesting areas for improvement such as increased transparency, stronger penalties, and better post-market surveillance. The discussion also touched upon the importance of public access to clinical trial data and the need for improved communication of drug risks.
On May 30, 2014, the House of Commons debated and moved Bill C-17, "Vanessa's Law", to a committee stage, alongside other House business including statements by members and oral questions on various topics.
This document is a record of a sitting of the House of Commons on May 30, 2014. During this sitting, the House debated and passed Bill C-17, also known as "Vanessa's Law", which aims to amend the Food and Drugs Act. The sitting also included other business, such as statements by members on various topics and oral questions on issues like veterans affairs, privacy, employment, and international development. The discussion on Bill C-17 focused on its second reading, where it was ultimately referred to a committee. The record also shows a point of order raised by an MP regarding time allocation for Bill C-17.
The House of Commons committee examined Bill C-17 in June 2014, a procedural step that has been completed.
This artifact details the 'Consideration in committee' stage for Bill C-17 in the House of Commons, which occurred on multiple dates in June 2014. This stage is where a legislative committee examines a bill clause by clause and can propose amendments. The records indicate this stage was completed.
This document records a House of Commons sitting on June 13, 2014, featuring debates on Bill C-18 (Agricultural Growth Act), statements by members on various topics, and oral questions directed at government ministers.
This artifact is a record of a sitting of the House of Commons on June 13, 2014. During this sitting, the House proceeded with "Government Orders", which included debate on Bill C-18, the Agricultural Growth Act. Several Members of Parliament from different parties spoke, raising concerns and providing commentary on various aspects of the bill. The record also includes "Statements by Members" on a variety of unrelated topics and "Oral Questions" where MPs questioned government ministers on different issues. Additionally, there are records of "Routine Proceedings," which include the introduction of new bills and the tabling of committee reports. This specific artifact details the debate and procedural movements within the House on this date, rather than the bill's ultimate legal effect or passage.
The House of Commons completed Report Stage and Third Reading for Bill C-17 on June 16, 2014, before it received Royal Assent on November 6, 2014.
On June 16, 2014, the House of Commons completed the Report stage for Bill C-17, An Act to amend the Food and Drugs Act. Following this, the House of Commons also completed Third reading for the bill on the same day. The bill later received Royal Assent on November 6, 2014, and became chapter 24 of the Statutes of Canada, 2014.
On June 16, 2014, the House of Commons debated and passed Bill C-17, the 'Protecting Canadians from Unsafe Drugs Act (Vanessa's Law)', at its report stage and third reading.
This record documents a sitting of the House of Commons on June 16, 2014. The primary focus was the report stage debate and subsequent passage of Bill C-17, the "Protecting Canadians from Unsafe Drugs Act (Vanessa's Law)". The debate included discussions on various other matters such as private members' business, government orders, statements by members, and oral questions covering a range of government policy areas. The artifact specifically details the procedural steps taken regarding Bill C-17.
Bill C-17 completed its Third Reading in the House of Commons on June 16, 2014, and then moved to the Senate.
This artifact indicates that Bill C-17 completed its Third Reading stage in the House of Commons on June 16, 2014. The process record notes that the bill was 'Agreed to' at this stage, as indicated in the Journals of the House of Commons (Journals 104). Following this, the bill proceeded to a First Reading in the Senate on the same day.
The House of Commons debated and passed Bill C-17, An Act to amend the Food and Drugs Act, during its third reading on June 16, 2014, following discussions on various other parliamentary matters.
On June 16, 2014, the House of Commons debated Bill C-17, An Act to amend the Food and Drugs Act, at its third reading stage. The sitting included debates on various other matters, including the Agricultural Growth Act, statements by members on a range of topics, oral questions on national defence, justice, the environment, and other subjects, as well as routine proceedings and government orders related to other bills. Ultimately, the debate on Bill C-17 concluded with its passage.
We don't have a plain-language summary for Debates of the Senate yet. The official source linked below is the full record.
Debate and sitting links point to official parliamentary sources when LEGISinfo publishes them. Any plain-language discussion summaries should be generated from those official texts and reviewed before public display.
Vote Summary
This bill does not have a published recorded division in the current official sources, so representative-by-representative vote counts are not shown.
No published representative vote breakdown
The current official sources do not publish a recorded division breakdown for this bill, so there is no representative-by-representative table to show.
Official sources
Status, sponsor, votes, and timeline on this page are drawn from these official legislative sources and public records. Each summary above is attributed to its own source.
How this data is sourced